Five Under 5: Top Oncology Videos for the Week of 1/26

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Aditya Shreenivas, MD, MS, an assistant professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, in California, spotlighted data from a gene expression profiling analysis of the association between claudin 18 and MUC1 in gastrointestinal cancers, and their potential implications for targeted therapy development.

Angeles Alvarez Secord, MD, MHSc, a professor of obstetrics and gynecology at Duke Cancer Institute, in North Carolina, reviewed findings from a consensus report published by the National Academies of Sciences, Engineering, and Medicine committee. Check out more insights from the 2025 SGO Winter Meeting.

Mansi R. Shah, MD, an assistant professor of medicine in the Division of Blood Disorders at Rutgers Cancer Institute of New Jersey, Robert Wood Johnson (RWJ) Medical School and hematologist/oncologist at RWJ University Hospital, detailed findings from a study presented at the 2024 ASH Annual Meeting, which examined the effects of intravenous immunoglobulin supplementation on infections in patients with relapsed/refractory multiple myeloma treated with teclistamab-cqyv (Tecvayli).

Aasma Shaukat, MD, MPH, Robert M. and Mary H. Glickman Professor of Medicine in the Department of Medicine and professor in the Department of Population Health at NYU Grossman School of Medicine; director of Outcomes Research in the Division of Gastroenterology and Hepatology; and codirector of Translational Research Education and Careers at NYU Langone Health, in New York, discussed the performance of a blood-based colorectal cancer screening test adjusted to the US census age and sex distribution. Data from the test were shared at the 2025 Gastrointestinal Cancers Symposium.

Guillermo Garcia-Manero, MD, professor and chief of the Section of Myelodysplastic Syndromes, deputy chair of Translational Research, fellowship program director in the Department of Leukemia of the Division of Cancer Medicine, chair and faculty senate at The University of Texas MD Anderson Cancer Center, in Houston, explained the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib (CA-4948) in myelodysplastic syndrome and acute myeloid leukemia.